Frontier Bio

Regenerating Human Tissue, Starting with Blood Vessels

https://wefunder.com/frontier.bio

Total raised on Wefunder: 477660

Total investors: 342

Quick facts

  • Award-Winning Data: Our graft grew a living lining in 14 days (2026 VESS Best Paper).
  • NIH/FDA Prize Winner: Won the Complement-ARIE challenge for human-based research models.
  • The Patient's Own Cells: Designed to be seeded with their stem cells in one surgery.
  • Elite Backing: SBIR-funded, backed by a Nobel Laureate, and advised by George Church.
  • Revenue-Backed: $5.5M in cumulative sales to customers including Mayo Clinic and Intuitive Surgical.
  • Patent Families: Defensible IP covering core tissue biofabrication and vascular graft technologies.

Team profiles

Featured investor profiles

Frontier Bio

Regenerating Human Tissue, Starting with Blood Vessels

Never miss an update

  • Join the Frontier Bio community. Follow their journey as they grow.
  • Stay in the loop if they ever decide to raise a round.

What Investors Say

LEAD INVESTOR
Invested $72,482 this round
At Asymmetry, we invest in technologies that turn science fiction into fact. Frontier Bio is doing exactly that with their lab-grown human tissues. It's rare to see a deeptech company achieve this level of capital efficiency. With a sales track record that speaks for itself and customers like Intuitive Surgical and Mayo Clinic, the team has proven they can deliver. With the FDA now encouraging alternatives to animal testing, Frontier Bio’s 'clinical trial in a dish' capabilities are perfectly timed. - Asymmetry Ventures
What People Say